Balstilimab + Botensilimab + Liposomal Doxorubicin

Phase 2Recruiting

1 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Newly Diagnosed Glioblastoma

Conditions

Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype, Gliosarcoma, Glioblastoma Multiforme

Trial Timeline

Jan 31, 2024 → Aug 1, 2026

NCT ID

NCT05864534

About Balstilimab + Botensilimab + Liposomal Doxorubicin

Balstilimab + Botensilimab + Liposomal Doxorubicin is a phase 2 stage product being developed by Agenus for Newly Diagnosed Glioblastoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05864534. Target conditions include Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype, Gliosarcoma.

What happened to similar drugs?

0 of 5 similar drugs in Newly Diagnosed Glioblastoma were approved

Approved (0) Terminated (1) Active (4)

🔄Olaparib 300mg tabletsAstraZenecaPhase 3

🔄Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimenAmgenPhase 3

🔄Elranatamab + Lenalidomide (Revlimid®) + Daratumumab SC (Darzalex) + Bortezomib (Velcade®) + DexamethasonePfizerPhase 3

❌Lenalidomide + Dexamethasone + ElotuzumabBristol Myers SquibbPhase 3

🔄Bortezomib + Isatuximab + Iberdomide + Lenalidomide + DexamethasoneBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05864534	Phase 2	Recruiting	Jan 31, 2024	Aug 1, 2026	Newly Diagnosed Glioblastoma

Competing Products

18 competing products in Newly Diagnosed Glioblastoma

See all competitors

Product	Company	Stage	Hype Score
PLX3397 + Temozolomide	Daiichi Sankyo	Phase 1/2	32
Gliadel Wafer + Temozolomide	Eisai	Phase 2	31
Olaparib 300mg tablets	AstraZeneca	Phase 3	44
Pembrolizumab	Merck	Phase 2	39
Drug (including placebo)	Merck	Phase 1	21
Cilengitide	Merck	Phase 2	31
[177Lu]Lu-NeoB + [68Ga]Ga-NeoB	Novartis	Phase 1	33
BKM120 + Trastuzumab + Paclitaxel + BKM120 Placebo	Novartis	Phase 2	35
Tecentriq 1200 MG in 20 ML Injection + H3K27M peptide vaccine	Roche	Phase 1	33
Zenapax	Roche	Phase 2	35
Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimen	Amgen	Phase 3	47
Elranatamab + Lenalidomide (Revlimid®) + Daratumumab SC (Darzalex) + Bortezomib (Velcade®) + Dexamethasone	Pfizer	Phase 3	47
Elranatamab + Daratumumab + Lenalidomide	Pfizer	Phase 2	42
Lenalidomide + Dexamethasone + Elotuzumab	Bristol Myers Squibb	Phase 3	32
Bortezomib + Isatuximab + Iberdomide + Lenalidomide + Dexamethasone	Bristol Myers Squibb	Phase 3	47
Isatuximab-Irfc 20 MG/ML [Sarclisa] + Lenalidomide + Dexamethasone Oral	Sanofi	Phase 2	39
Mebendazole	Brain Biotech	Phase 1	19
HLA-A2 restricted glioma antigen peptides vaccine + Poly-ICLC	Brain Biotech	Phase 1	19